Three suggestions for defusing the highly charged pricing atmosphere
The agency announced a new committee to help integrate patient perspectives into the regulation of medical devices.
The pharma business needs to take engagement far more seriously than it has in the past. At the same time, there are signs that the industry is finally acting with more urgency and even transparency.
An inVentiv Health study indicates patient groups want more say in drug development and patient support.
Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.
Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma company to pair with the Crohn's and Colitis Foundation of America.
CureDuchenne is giving biotech Prosena $7 million to help its Duchenne Muscular Dystrophy treatment move along.
Patient use of the professional app prompted the latest iteration, and the foundation behind it is set to launch a media push.
J&J sells off its feminine side; Manhattan Research's study on the sales rep "tablet dance"; Cepheid rolls out a consumer TB campaign; and healthcare sector job losses top out in July.
Execs told Weber Shandwick that internal hurdles such as insufficient expertise and unclear ROI measures are really what's keeping them from the social-media mix.
A Novartis survey finds many women with advanced breast cancer feel left out by an awareness movement focused on prevention, early detection and pink merchandise.
Jolie takes on cancer awareness role, researchers identify another adherence gap, Sanofi gets slapped for scare tactics, Teva may compete for Adcock, AbbVie R&D chief leaves
A new FDA site gives patients a one-stop shop for commenting on pending regulations, finding clinical trials and navigating treatment options.
Genzyme is taking rare disease awareness to another level with a documentary film, dubbed "Facing Fabry Together," that follows four families grappling with the genetic disorder.
CDC figures suggest patients are avoiding medications to save money, and show that out-of-pocket costs for US consumers are rising faster than those for consumers in many other countries
Executives from big pharma pulled few punches on the opening day of eyeforpharma's Barcelona 2013 conference, lambasting their industry for its failure to adequately serve patients and develop enough innovative products.
MS patients have an "insatiable appetite" for information about treatments online, particularly the new class of oral treatments, whose manufacturers could be doing more to prep them for switch conversations, a survey suggests.
Industry observances of Rare Disease Awareness Day are getting more elaborate of late—perhaps not solely for altruistic reasons, as a third of NMEs approved by FDA over the past five years were for the treatment of rare diseases.
A program to create a crowdsourced disease registry was crowned the winner of Sanofi's inaugural Collaborate Activate Innovation Challenge, a contest that rewards collaboration among patient and medical advocacy groups.
Consumer advocacy group Community Catalyst declared war on prescription co-pay cards and coupons, saying the sales tools are nothing more than kickbacks and bribes.
Health information site HealthCentral has been acquired by Remedy Health, a multimedia provider of content and tools designed to help people manage disease, the firms said today.
Pfizer Oncology has recruited Desperate Housewives and West Wing star Kathryn Joosten to feature in a national education campaign titled Lung Cancer Profiles, which aims to reduce stigma and plug molecular testing of the disease as the company deepens its investment in genetically-targeted oncology therapies.
The House's passage of the National Alzheimer's Project Act yesterday - should it be signed into law by President Obama - could help expedite the approval process for new drugs targeting the disease, sources say.
Patient advocacy groups are an increasingly valuable resource for pharma manufacturers and FDA throughout the drug development process, since they provide, among other things, a crucial perspective, according to a New York Pharma Forum panel last week.